Vulnerability in Drug Supply Chains Exposes Critical gaps

South Korea faces meaningful challenges in securing a stable supply of essential medicines, especially when compared to other leading nations. Experts are advocating for proactive legislative measures and complete supply chain mapping to mitigate potential disruptions and ensure national health security.

The Urgency of a “Pharmaceutical Bio Supply Stabilization Act”

Chung Soon-kyu, a leading expert from the Korea Health Industry development Institute (KHIDI), emphasizes the critical need for a “Pharmaceutical Bio Supply Stabilization Act.” This proposed legislation aims to address vulnerabilities in the pharmaceutical supply chain and bolster domestic capabilities. We are pushing for countermeasures, but Korea is relatively insufficient to establish a pharmaceutical supply chain stabilization system, Chung stated, highlighting the current inadequacy of existing measures.

Current Support falls Short

While initiatives such as R&D support for new epidemic disease treatments and domestic consignment manufacturing of essential drugs exist, they are insufficient.A critical gap remains in supporting domestic companies in securing raw materials, expanding manufacturing facilities, and developing national raw material sources. This lack of comprehensive support leaves South Korea vulnerable to global supply chain disruptions.

Global Reliance and Domestic Shortages

A survey by the Korea Pharmaceutical Bio Association reveals the extent of global reliance on a few key players. China dominates raw material pharmaceutical production with 44% of the market share, followed by India with 20%. This concentration of production creates potential risks for countries dependent on these sources.

South Korea has already experienced drug shortages, with 46 essential medicines facing production or import challenges in the three years leading up to November of last year. As of April of last year, 490 drugs were classified as unstable, including 95 domestically produced items.

geopolitical Shifts and Supply Chain Instability

The global pharmaceutical supply chain is on the cusp of significant transformation due to various factors, including high-rate tariff policies, China’s strategic responses, and evolving supply chain regulations in japan and Europe. These geopolitical shifts, coupled with ongoing conflicts like the Russian-Ukrainian war and climate change-induced weather disasters, are creating unprecedented instability.

Since this year, the global pharmaceutical supply chain is expected to change significantly due to the high -rate tariff policy, China’s response, and changes in supply chain regulations in japan and Europe.

Securing the Future: A Path to Pharmaceutical Independence

To ensure a stable and secure supply of essential medicines, South Korea must prioritize the enactment of the “Pharmaceutical Bio Supply Stabilization Act.” This legislation should focus on:

• Incentivizing domestic production of raw materials and active pharmaceutical ingredients (APIs).
• investing in advanced manufacturing technologies and expanding domestic production capacity.
• Diversifying supply chains to reduce reliance on single-source suppliers.
• Establishing a national stockpile of essential medicines and raw materials.
• Strengthening international collaborations to ensure access to critical medicines during emergencies.

By taking these proactive steps, South Korea can enhance its pharmaceutical independence and safeguard the health and well-being of its citizens.

Addressing Vulnerabilities: A New Era for Pharmaceutical Independence

In response to escalating global tensions and vulnerabilities exposed in international supply chains, South Korea is taking decisive steps to fortify its pharmaceutical sector. The initiative aims to ensure a stable and reliable supply of essential medicines for its citizens, reducing dependence on foreign sources and fostering domestic innovation.

strategic Measures for Supply Chain Resilience

The government is prioritizing the establishment of a comprehensive management system that encompasses strategic facility investments, enhanced production capabilities, and robust reserve management. This multi-faceted approach seeks to guarantee public access to critical treatments without disruption.

Legislative Action: The ‘pharmaceutical and Bio Supply Stabilization Act’

At the heart of this initiative is the proposed enactment of the ‘Pharmaceutical and Bio Supply Stabilization Act’ (tentative name). This legislation is envisioned as the cornerstone for improving the nation’s pharmaceutical security.

It is indeed essential to establish a comprehensive management system that encompasses facility investment (securing manufacturing capabilities) and production and reserve management to ensure that the public can be treated with confidence thru the stable management of pharmaceutical supply chains.

Unnamed Government Official

Harnessing Technological Prowess: ICT Integration

Recognizing its strengths in data and communication technology (ICT), South Korea intends to leverage big data, artificial intelligence (AI), and blockchain technologies to optimize pharmaceutical supply chains. This integration promises enhanced transparency,efficiency,and security across the entire process,from manufacturing to distribution.

Korea has a strong ICT capacity, so it has good conditions for combining technology such as big data, artificial intelligence (AI), and blockchain into pharmaceutical supply chains.

Unnamed Government Official

Such as, blockchain could be used to track and trace pharmaceuticals, preventing counterfeiting and ensuring product integrity. AI algorithms can predict demand fluctuations, optimizing inventory levels and minimizing waste. According to a recent report by McKinsey, the application of AI in supply chain management can reduce forecasting errors by up to 50%.

Supporting Domestic Bio Companies: A Path to Global expansion

The government is also committed to supporting domestic pharmaceutical and bio companies. This includes providing crucial information on government procurement practices in major countries, particularly concerning biosimilars.By facilitating technology exports, raw material exports, and the acquisition of local manufacturing facilities abroad, south Korea aims to empower its companies to compete on a global scale.

Monitoring and Analysis: The ‘Supply Building Basic Law’

Under the framework of the ‘Supply Building Basic Law’, a comprehensive analysis and monitoring system of both domestic and foreign pharmaceutical supply chains is being implemented. This includes detailed surveys of supply chain status and the collection of relevant statistics, providing a data-driven foundation for informed decision-making.

Visual Depiction